March 29, 2021
Astellas Pharma said on March 26 that the European Medicines Agency (EMA) has accepted a regulatory submission for the antibody-drug conjugate (ADC) enfortumab vedotin, being codeveloped with its US partner Seagen, formally called Seattle Genetics. The submission rides on the...read more